Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer

Gastrooesophageal Cancer Clinical Trial

— DECIPHER  

Official title:

A Single Arm Phase II Trial of Trastuzumab Deruxtecan in Patients With Gastrooesophageal Adenocarcinoma Cancer Who Are ctDNA and HER2 Positive

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05965479
• Other study ID #: 68838
• Secondary ID: 2022-003445-34
• Status: Recruiting
• Phase: Phase 2
• Start date: April 10, 2024
• Est. completion date: April 30, 2028

Study information

• Verified date: May 2024
• Source: University of Southampton
• Contact: Elizabeth Smyth
• Phone: 023 81205773
• Email: elizabeth.smyth2[@]nhs.net
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Multicentre, single arm, open label UK phase II trial to assess the efficacy of trastuzumab deruxtecan in reducing micrometastatic disease burden in HER2 positive GOA patients who are ctDNA positive after chemotherapy and surgery. 25 patients will be recruited from approximately 15 NHS secondary care sites.

Description:

Gastrooesophageal (GOA) cancer is a common, global cancer which often presents at an advanced stage. Those diagnosed early will generally have neoadjuvant treatment with FLOT chemotherapy followed by surgery followed by the same FLOT chemotherapy post surgery. Treatment however is curative in less than 50%. Circulating tumour DNA (ctDNA) is found in the bloodstream. It refers to DNA that comes from cancerous cells and tumours. If ctDNA is positive it means that there are microscopic traces of tumour in the bloodstream (minimal residual disease). Patients who are ctDNA positive after chemotherapy and surgery are less likely to benefit from further FLOT chemotherapy and more likely to relapse. HER2 positive describes cells that have a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Cancer cells that make too much HER2 may grow more quickly and are more likely to spread to other parts of the body. Trastuzumab deruxtecan (T-DXd) is an antibody that targets HER2 cells. It attaches to the HER2 cells on the tumour and destroys them. In the UK, trastuzumab deruxtecan (Enhertu) is currently offered to patients with advanced breast cancer who are HER2 positive. In the US, Israel and Japan it is licenced in patients with advanced HER2 positive GOA. DECIPHER aims to treat patient's with GOA post-surgery who are both HER2 and ctDNA positive with trastuzumab deruxtecan (Enhertu) instead of standard care FLOT chemotherapy. The aim of the trial is to treat the minimal residual disease reducing the chance of relapse. All trial patients will be followed for up to 2 years to record their response to treatment. 25 patients will be recruited over 18 months. Patients will be treated with 6.4 mg/kg trastuzumab deruxtecan every 21 days for 8 cycles.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: April 30, 2028
• Est. primary completion date: March 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pathologically documented adenocarcinoma of the stomach (clinical stage before surgery of AJCC I-III), gastroesophageal junction, or lower oesophagus (to include Type I Siewert only), with HER2 overexpression (IHC 3+ or IHC 2+/ISH+) based on local tissue testing results.
• ctDNA positive after surgery as per Signatera assay
• Capable of giving signed informed consent prior to any mandatory study specific procedures, sampling, or analyses and which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
• Male and female participants must be at least 18 years of age at the time of signing the ICF.
• Treated with neoadjuvant chemotherapy before surgery for at least six weeks.
• Surgical resection with clear margins (R0).
• Recovered from surgery in the opinion of the investigator.
• No previous treatment with trastuzumab or other HER2 directed therapy.
• No evidence of metastatic disease on post-surgical CT.
• Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
• Has LVEF = 50% by either echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before treatment.
• Has adequate organ and bone marrow function within 14 days before treatment allocation

as below:

• Platelet count = 100x109/L (Platelet transfusion is not allowed within 1 week prior to screening assessment, use of thrombopoietin receptor agonists is not allowed within 2 weeks prior to screening assessment)
• Haemoglobin = 80 g/L. Participants requiring transfusions or growth factor support to maintain haemoglobin = 80 g/L are not eligible. (Red blood cell transfusions is not allowed within 1 week prior to screening assessment)
• Absolute neutrophil count = 1.5 x 109/L (granulocyte-colony stimulating factor [G-CSF] administration is not allowed within 1 week prior to screening assessment
• ALT/AST = 3 x ULN
• Total bilirubin = 1.5 x ULN or < 3 x ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia)
• Serum albumin = 3.0 g/dl
• Creatinine clearance = 50 mL/min as calculated using the Cockcroft-Gault equation
• Adequate clotting function International Normalized Ratio (INR) or prothrombin time and either partial thromboplastin or activated partial thromboplastin time (aPTT) = 1.5 x ULN.
• Reproduction:
• Evidence of post-menopausal status or negative serum pregnancy test for females of childbearing potential who are sexually active with a non-sterilised male partner.
• For women of childbearing potential, a negative result for serum pregnancy test (test must have a sensitivity of at least 25 mIU/mL) must be available at the screening visit and urine beta-human chorionic gonadotropin (ß-HCG) pregnancy test prior to each administration of IMP.
• Women of childbearing potential are defined as those who are not surgically sterile (i.e., underwent bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or post-menopausal. I. Women aged <50 years will be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the site. II. Women aged = 50 years will be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses > 1 year ago, had chemotherapy-induced menopause with last menses >1 year ago.
• Female participants of childbearing potential who are sexually active with a non-sterilised male partner must use at least one highly effective method of contraception from the time of screening, and must agree to continue using such precautions for 7 months after the last dose of IMP. Not all methods of contraception are highly effective.
• Female participants must refrain from breastfeeding and must not donate (or retrieve their own for use) ova, from the time of screening, throughout the study treatment period, and for at least 7 months after the last dose of IMP.
• Complete heterosexual abstinence for the duration of the study and drug washout period is an acceptable contraceptive method if it is in line with the patient's usual lifestyle (consideration must be made to the duration of the clinical trial); however, periodic or occasion abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.
• Non-sterilised male participants who are sexually active with a female partner of childbearing potential must use a condom with spermicide from screening to 4 months after the final dose of IMP.
• It is strongly recommended for the female partners of a male participant to also use at least one highly effective method of contraception throughout this period. In addition, male participants should refrain from fathering a child or freezing or donating sperm from screening, throughout the study treatment period, and for at least 4 months after the last dose of IMP.
• Investigators should advise male participants on the conservation of sperm prior to starting treatment because of the possibility of irreversible infertility/testicular damage due to IMP administered in this study.
• Female subjects must not donate, or retrieve for their own use, ova from the time of enrolment and throughout the study treatment period, and for at least 7 months after the final study drug administration. They should refrain from breastfeeding throughout this time. Preservation of ova prior to enrolment in this study, can be discussed with the patient if clinically appropriate to do so.

Exclusion Criteria:

• Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AE's, or compromise the ability of the participant to give written informed consent.
• Participants with a medical history of myocardial infarction within 6 months before treatment or symptomatic CHF (New York Heart Association Class II to IV), unstable angina pectoris, clinically important cardiac arrhythmias, or a recent (<6 months) cardiovascular event, including myocardial infarction, unstable angina pectoris, and stroke. Participants with troponin levels above ULN at screening (as defined by the manufacturer)m and without myocardial related symptoms, should have a cardiologic consultation before enrolment to rule out myocardial infarction.
• Corrected QT interval (QTcF) prolongation to > 470 msec (females) or > 450 msec (males) based on average of the screening triplicate 12-lead ECG
• History of (non-infectious) ILD/pneumonitis, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
• Any of the following:

1. Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g., clinically significant pulmonary emboli within 3 months of treatment, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, clinically significant pleural effusion etc.)

2. Any autoimmune, connective tissue, or inflammatory disorders with pulmonary involvement (e.g., rheumatoid arthritis, Sjogren's, sarcoidosis etc.), where there is documented, or a suspicion of, pulmonary involvement at the time of screening

3. Prior pneumonectomy (complete)

• Uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals
• Multiple primary malignancies within the prior 3 years, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumours curatively treated.
• A pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt.
• Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade =1 or baseline. The following exemption will apply; stable chronic G2 toxicity which in the opinion of the investigator is not reasonably expected to be exacerbated by treatment with study drugs.
• Known allergy or hypersensitivity to T-DXd or any of the study drug components
• History of severe hypersensitivity reactions or other monoclonal antibodies
• Pregnant or breastfeeding female participants, or participants who are planning to become pregnant
• Involvement in the planning and/or conduct of the study
• Has substance abuse or any other medical conditions, that may, in the opinion of the investigator, interfere with the subjects participation in the clinical study or evaluation of the clinical study results
• Receipt of live, attenuated vaccine within 30 days prior to the first dose of trastuzumab deruxtecan. Note: Patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IMP
• Active primary immunodeficiency, known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection. Patients positive for hepatitis (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
• Judgement by the Investigator that the participant should not participate in the study, if the participant is unlikely to comply with study procedures, restrictions, and requirements.

Related Conditions & MeSH terms

• Gastrooesophageal Cancer

Intervention

Drug:
• Trastuzumab deruxtecan
Trastuzumab deruxtecan is an antibody-drug conjugate that contains trastuzumab covalently linked to deruxtecan, a topoisomerase I inhibitor. It is given by intravenous infusion.

Locations

Country	Name	City	State
United Kingdom	Belfast Health and Social Care Trust, Belfast City Hospital	Belfast
United Kingdom	Cambridge University Hospital NHS Foundation Trust, Addenbrookes Hospital	Cambridge
United Kingdom	University Hospitals Coventry and Warwickshire, University Hospital Coventry	Coventry	Warwickshire
United Kingdom	University Hospitals of Derby and Burton NHS Foundation Trust, Royal Derby Hospital	Derby
United Kingdom	NHS Tayside, Ninewells Hospital	Dundee
United Kingdom	Royal Surrey NHS Foundation Trust, Royal Surrey County Hospital	Guildford	Surrey
United Kingdom	Hull University Teaching Hospitals NHS Trust, Castel Hill Hospital	Hull
United Kingdom	Leeds Teaching Hospitals NHS Trust, St James's University Hospital	Leeds
United Kingdom	Guys & St Thomas NHS Foundation Trust, Guy's Hospital	London
United Kingdom	University College London Hospitals NHS Foundation Trust, University College Hospital London	London
United Kingdom	The Christie NHS Foundation Trust	Manchester
United Kingdom	Norfolk and Norwich University Hospitals NHS Foundation Trust, Norfolk and Norwich University Hospital	Norwich
United Kingdom	Oxford University Hospitals NHS Trust, Churchill Hospital	Oxford
United Kingdom	Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital	Preston
United Kingdom	University Hospital Southampton NHS Foundation Trust, Southampton General Hospital	Southampton	Hampshire
United Kingdom	Velindre University NHS Trust, Velindre Cancer Centre	Whitchurch

Sponsors (3)

Lead Sponsor	Collaborator
University of Southampton	AstraZeneca, Natera, Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Measurement of the quantity of ctDNA present in blood using the Signatera assay	Absolute and relative ctDNA reduction in individual patients, duration of ctDNA response, correlation between ctDNA response and radiological recurrence and survival outcomes	From date of surgery until the date of recurrence or date of death from any cause, whichever comes first, assessed up to 30 months
Other	Measurement of the quantity of ctDNA present in blood using Signatera assay	Correlation between tumour HER2 IHC and copy numbers status, other molecular markers and ctDNA dynamics and patient outcomes	From date of surgery until the date of recurrence or date of death from any cause, whichever comes first, assessed up to 30 months
Primary	ctDNA clearance	Percentage of people who are classed ctDNA negative, as measured by the Signatera assay	At the end of Cycle 4 (each cycle is 21 days)
Secondary	ctDNA clearance (yes/no)	Percentage of people who are ctDNA negative after each cycle	Up to completion of cycle 8 (where each cycle is 21 days)
Secondary	Disease Free Survival	Time from surgery to recurrence of macroscopic disease of radiological imaging or death	At 12 months and 24 months
Secondary	Overall survival	Time from surgery to death	12, 18 and 24 months
Secondary	QLQ-C30	Quality of life scored from QLQ-C30	Up to 30 months post surgery
Secondary	QLQ-OG25	Quality of life scored from QLQ-OG25	Up to 30 months post surgery
Secondary	EQ-5D-5L	Quality of life scored from EQ-5D-5L	Up to 30 months post surgery
Secondary	Safety and tolerability of T-DXd	Frequency of adverse events and percentage of people experiencing them	Up to 100 days post last dose of trial treatment